Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) granted an inducement equity award to new Chief Financial Officer Jennifer Larson, effective August 12, 2026, under its 2026 Inducement Plan. The award consists of a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, equal to the Nasdaq closing price on the grant date.

According to Bicara, one-fourth of the option vests on the first anniversary of Larson’s start date, with the balance vesting in 12 equal quarterly installments thereafter, contingent on continued service. The grant was made outside stockholder-approved equity plans under the 2026 Inducement Plan, adopted in January 2026, and was unanimously approved by independent directors in line with Nasdaq Listing Rule 5635(c)(4).

Positive

• CFO inducement option for 285,000 shares aligns compensation with shareholders
• Exercise price set at market closing price of $24.63 on grant date
• Structured vesting over more than four years supports leadership retention

Negative

• Inducement grant outside stockholder-approved plans adds potential equity dilution

News Market Reaction – BCAX

+2.75%

+2.75% Session close to close

In the Aug 14 session, BCAX gained 2.75%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Bicara's recent history included a 4.03% positive reaction to clinical data, a useful platform bench...

Analysis

Bicara's recent history included a 4.03% positive reaction to clinical data, a useful platform benchmark for evaluating this CFO inducement grant rather than treating the award in isolation. Recent Net Selling adds sentiment context, while the award's vesting terms remain the key structural detail.

Key Figures

Option Shares: 285,000 shares Exercise Price: $24.63 per share Par Value: $0.0001 per share +3 more

6 metrics

Option Shares 285,000 shares CFO inducement grant

Exercise Price $24.63 per share Option grant effective August 12, 2026

Par Value $0.0001 per share Bicara common stock

Effective Date August 12, 2026 Inducement grant

Initial Vesting One-fourth of the shares First anniversary of start date

Remaining Vesting 12 equal quarterly installments Subject to continued service

Historical Context

5 past events · Latest: Aug 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Leadership transition	Positive	-14.2%	Leadership succession and clinical progress update preceded a -14.17% 24-hour reaction
Aug 04	Earnings scheduling	Neutral	+1.4%	Company scheduled second-quarter results and business updates for August 11
Jul 28	Board appointments	Positive	-3.3%	Two directors joined the board before a -3.34% 24-hour reaction
Jul 02	Inducement grants	Neutral	+0.3%	Four employees received inducement equity awards with time-based vesting
May 21	Clinical data	Positive	+4.0%	Three-year overall survival data supported the ongoing pivotal program

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent management-related announcements diverged negatively, while the prior inducement-grant notice had a positive reaction.

Key Terms

inducement grant, non-qualified stock option, par value, nasdaq listing rule 5635(c)(4)

4 terms

inducement grant financial

"today announced that, effective August 12, 2026, it awarded an inducement grant"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

non-qualified stock option financial

"Ms. Larson received a non-qualified stock option to purchase 285,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

par value financial

"common stock, par value $0.0001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara’s 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara’s Chief Financial Officer.

Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on August 12, 2026. One-fourth of the shares vest on the first anniversary of Ms. Larson’s start date, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to her continued service with Bicara through each applicable vesting date.

Ms. Larson’s award was granted outside of Bicara’s stockholder-approved equity incentive plans and is pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The award was unanimously approved by Bicara’s independent directors as a material inducement to Ms. Larson’s employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential adverse effects previously associated with systemic TGF-β inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors:
Rachel Frank
IR@bicara.com

Media:
Tim Palmer
tim.palmer@bicara.com

FAQ

What did Bicara Therapeutics (BCAX) announce about Jennifer Larson’s compensation on August 14, 2026?

Bicara Therapeutics announced a non-qualified stock option grant to CFO Jennifer Larson for 285,000 shares. According to Bicara, the inducement award was granted under its 2026 Inducement Plan as a material inducement to her commencement of employment.

What are the terms of Jennifer Larson’s stock option grant at Bicara Therapeutics (BCAX)?

Jennifer Larson received options to purchase 285,000 BCAX shares at an exercise price of $24.63 per share. According to Bicara, the price equals the August 12, 2026 Nasdaq closing price of its common stock.

How do Jennifer Larson’s Bicara (BCAX) stock options vest under the 2026 Inducement Plan?

The options vest 25% on the first anniversary of her start date, then in 12 equal quarterly installments. According to Bicara, vesting is subject to Larson’s continued service through each applicable vesting date.

Why did Bicara Therapeutics (BCAX) grant the CFO stock options outside stockholder-approved plans?

Bicara granted the award outside its stockholder-approved plans under the 2026 Inducement Plan. According to Bicara, independent directors unanimously approved it as a material inducement to Jennifer Larson’s employment under Nasdaq Listing Rule 5635(c)(4).

What is Nasdaq Listing Rule 5635(c)(4) and how does it relate to Bicara (BCAX)?

Nasdaq Listing Rule 5635(c)(4) allows inducement equity grants for new employees under specific conditions. According to Bicara, Larson’s option grant was approved as a material inducement to employment consistent with this rule and issued under the 2026 Inducement Plan.

When was Bicara Therapeutics’ 2026 Inducement Plan adopted for BCAX equity grants?

Bicara’s 2026 Inducement Plan was adopted by the board of directors in January 2026. According to Bicara, the plan enabled the August 12, 2026 inducement option grant to CFO Jennifer Larson outside stockholder-approved equity incentive plans.